옵션 체인은 다양한 행사가격과 만기일에 대한 Canaan의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Canaan에 대한 시장 심리를 평가합니다..

Canaan (NASDAQ:CAN) 주식, 옵션 체인

Canaan

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

News

Previews

Global

Movers

$BTC

BITF

HIVE

비트코인(CRYPTO: BTC)이 도널드 트럼프의 당선 이후 사상 최고가로 급등했으며, 이는 긍정적인 시장 심리의 파도로 비트코인 채굴 관련 주식들도 상승하는 결과를 가져왔다.

비트코인이 최고가를 경신하는 가운데 채굴업체 하이브 디지털, 헛 8 및 비트팜즈 실적 발표

Canaan Inc

Can B Corp

Tema Oncology ETF

Teucrium Sugar Fund ETV

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd

Cango Inc. American Depositary Shares, each representing two (2) Class A Ordinary Shares

Cango Inc

CannLabs Inc

Trees Corp

CALIFORNIA NANOTECHS CORP by California Nanotechnologies Corp

California Nanotechnologies Corp

Cano Health Inc Ordinary Shares - Class A

Cano Health Inc Warrants (03/06/2026)

Cian PLC

Calamos Alternative Nasdaq & Bond ETF

CANAQUEST MED CORP by CanaQuest Medical Corporation

CanaQuest Medical Corp

CANARE ELECTRIC CO LTD by CANARE ELECTRIC CO LTD

Canare Electric Co Ltd

WILLOW BIOSCIENCES INC by Willow Biosciences Inc.

Willow Biosciences Inc

CAVENDISH HYDROGEN ASA by CAVENDISH HYDROGEN ASA

<a href="https://grizzlyreports.com/we-believe-sharkninja-inc-nyse-sn-is-a-china-hustle-based-on-rampant-looting-and-conflicts-of-interest-with-the-chinese-chairman/" title="https://grizzlyreports.com/we-believe-sharkninja-inc-nyse-sn-is-a-china-hustle-based-on-rampant-looting-and-conflicts-of-interest-with-the-chinese-chairman/">https://grizzlyreports.com/we-believe-sharkninja-inc-nyse-sn-is-a-china-hustle-based-on-rampant-looting-and-conflicts-of-interest-with-the-chinese-chairman/</a>

Short Sellers

Trading Ideas

Watching Shares Of SharkNinja; Grizzly Research Issues Report On The Co. Titled, "We Believe SharkNinja, Inc is a China Hustle Based on Rampant Looting and Conflicts of Interest with the Chinese Chairman"

Cannabis operator with vertical operations in Arizona and Ohio Vext Science, Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/VEXT#CSE">VEXT</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/VEXTF#OTCQX">VEXTF</a>) reported on its financial results Thursday for the period ended Sept. 30, 2024.
&#8220;Vext&#8217;s performance in the third quarter of 2024 was a testament to the team&#8217;s disciplined execution amid persistent macroeconomic headwinds," Eric Offenberger, CEO of Vext, said. "Our solid Adjusted EBITDA results reflect both the transition to adult-use sales in Ohio, as well as our focus on maintaining strict cost control. Despite a challenging economic climate and typical third-quarter seasonality and pricing pressures in the Arizona market with the ongoing supply-demand imbalance, we&#8217;re pleased to report that our economic unit volumes remain strong."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40463152/vext-cannabis-co-s-q2-revenue-drops-over-8-yoy-but-top-cannabis-analyst-sees-ohio-market-as-majo">Vext Cannabis Co.&#8217;s Q2 Revenue Drops Over 8% YoY, But Top Cannabis Analyst Sees Ohio Market As Major Growth Driver</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Q3 2024 Financial Highlights</h3>
<ul>
<li>Revenue totaled roughly $9 million, up from $8 million in the prior year's period.</li>
<li>Gross profit was $3.9 million, up from $2.8 million in the third quarter of last year.</li>
<li>Total operating expenses amounted to $5.2 million, up from $4.5 million in the corresponding quarter of 2023.</li>
<li>Adjusted EBITDA amounted to approximately $2.9 million, up from $1 million in the third quarter of 2023.</li>
<li>Net loss was $2.5 million, up from $1.8 million in the prior year's period.</li>
</ul>
<h3 class="wp-block-heading">Outlook</h3>
The company noted that it's well-positioned to increase its Ohio footprint with an integrated approach.
Vext aims to open more dispensaries in Ohio by 2025–2026, anticipating reaching the state's dispensary cap of 8.
Pablo Zuanic, senior analyst at Zuanic &amp; Associates initiated coverage of Vext Science with an Overweight rating earlier this year, highlighting the company&#8217;s significant growth potential.
Zuanic calculated that Vext has the most EBITDA torque among the twelve public multi-state operators (MSOs) in Ohio, projecting Vext&#8217;s EBITDA could grow six-fold by calendar 2026, taking calendar 2023 as the base year. Recreational marijuana sales launched across Ohio on <a href="https://www.benzinga.com/markets/cannabis/24/08/40172821/its-official-ohio-begins-recreational-cannabis-sales-on-tuesday-heres-where-and-how-you-know-the">Tuesday, Aug. 6.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40761882/1b-in-26-days-this-marijuana-company-is-capitalizing-on-ohios-cannabis-surge">$1B In 26 Days: This Marijuana Company Is Capitalizing On Ohio's Cannabis Surge</a></li>
</ul>

Cannabis

Retail Sales

CSE:VEXT

VEXTF

Ohio's Weed Enthusiasts Help This Cannabis Company's Bottom Line: 165% YoY Increase In Q3 Adjusted EBITDA

RBC Capital analyst Steven Shemesh maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and raises the price target from $162 to $189.

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Williams-Sonoma, Raises Price Target to $189

B of A Securities analyst Robert Ohmes maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Buy and lowers the price target from $195 to $160.

B of A Securities Maintains Buy on Target, Lowers Price Target to $160

RBC Capital analyst Brad Erickson maintains Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) with a Outperform and raises the price target from $190 to $245.

RBC Capital Maintains Outperform on Wix.com, Raises Price Target to $245

BMO Capital analyst Michael Zaremski maintains Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) with a Market Perform and raises the price target from $445 to $461.

KNSL

BMO Capital Maintains Market Perform on Kinsale Cap Gr, Raises Price Target to $461

Deere CFO Says Expect Farm Fundamentals To Remain Depressed Globally In 2025; Executive Says Production Costs For Fy Came In Favorable, Primarily Due To YoY Improvements In Material And Freight Costs Across All Business Segments

Barclays analyst David Zazula maintains Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) with a Underweight and raises the price target from $0.75 to $2.

EVTL

Barclays Maintains Underweight on Vertical Aerospace, Raises Price Target to $2

BMO Capital analyst Michael Zaremski maintains Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) with a Underperform and raises the price target from $13 to $15.

LMND

BMO Capital Maintains Underperform on Lemonade, Raises Price Target to $15

Barclays analyst Matthew Bouley maintains AZEK Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) with a Overweight and raises the price target from $53 to $58.

AZEK

Barclays Maintains Overweight on AZEK Co, Raises Price Target to $58

At the recent <a href="https://cannabismarketspotlight.com/california/anaheim-november-12/">Cannabis Market Spotlight</a> event in Anaheim, California, Department of Cannabis Control director Nicole Elliott addressed some of the state's pressing cannabis industry challenges, zeroing in on tax reform and hemp regulation as two priority areas. 
As the state's top cannabis regulator, Elliott provided a window into the Department&#8217;s goals as it navigates an increasingly complex regulatory landscape while striving to support industry growth and public health objectives.
<h3 class="wp-block-heading">Tackling Tax Challenges</h3>
Elliott spoke to the ongoing challenges posed by the state's current tax framework for cannabis businesses. Acknowledging the financial burdens and inefficiencies that affect operators, she explained how these tax issues undermine the state's cannabis objectives.
See Also: <a href="https://www.benzinga.com/24/11/42111795/californias-cannabis-future-why-one-expert-believes-the-market-will-hold-strong">California&#8217;s Cannabis Future: Why One Expert Believes The Market Will Hold Strong</a>
"We know taxes will be an issue," Elliott noted, emphasizing the importance of constructive engagement between industry participants and legislators. She encouraged those in the cannabis space to approach the state legislature with clear, informed communication to help shape effective tax reforms.
<h3 class="wp-block-heading">Hemp Regulation and Unregulated Market Enforcement</h3>
Elliott also addressed the recent California court decision upholding restrictions on certain hemp products. While the California Department of Public Health manages hemp regulations, Elliott's department is involved in enforcing regulations within unregulated markets. Her team also serves as an advisor on cannabinoid products and regulatory standards. 
"We are serving as a subject matter expert when it comes to cannabinoid products, cannabinoid regulations," she shared, describing the department's role in guiding policy that aligns with California's public health and regulatory goals.
At the event, Elliott's comments offered industry professionals insights into the state's regulatory priorities, signaling areas of focus and potential legislative action as they prepare for what lies ahead in 2025.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42111313/exclusive-fluent-launches-new-cannabis-concentrates-line-for-medical-marijuana-patients-in-florida">FLUENT Launches New Cannabis Concentrates Line For Medical Marijuana Patients In Florida</a></li>
</ul>
Image: AI-Generated Image

Events

Exclusives

Interview

From Tax Woes To Hemp Rules: Department Of Cannabis Control's Nicole Elliott Outlines Regulatory Goals

U.S. stocks traded higher this morning, with the Dow Jones index gaining by more than 100 points on Thursday.
The Dow traded up 0.30% to 43,539.98 while the NASDAQ rose 0.01% to 18,968.98. The S&amp;P 500 also rose, gaining, 0.17% to 5,926.95.
Check This Out: <a href="https://www.benzinga.com/24/11/42086207/jim-cramer-likes-devon-energy-but-says-this-energy-stock-is-far-superior-to-devon">Jim Cramer Likes Devon Energy, But Calls Another Stock &#8216;Far Superior</a>&#8216;
Leading and Lagging Sectors Industrials shares rose by 0.7% on Thursday.
In trading on Thursday, communication services shares fell by 2.1%.
Top Headline
NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) reported better-than-expected earnings for its third quarter on Wednesday.
The company reported third-quarter revenue of $35.1 billion, up 94% year-over-year, which beat a Street consensus estimate of $33.12 billion, according to data from Benzinga Pro. Nvidia said it expects fourth-quarter revenue to be $37.5 billion plus or minus 2%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) shares shot up 29% to $4.76. Quantum Computing announced it received another purchase order for its photonic chip foundry.</li>
<li>Shares of Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) got a boost, surging 31% to $169.66 after the company reported stronger-than-expected results for its third quarter. Snowflake expects fourth-quarter product revenue in the range of $906 million to $911 million, up approximately 23% year-over-year. The company also raised its full-year product revenue guidance from $3.356 billion to $3.43 billion, representing 29% year-over-year growth.</li>
<li>Universal Technical Institute, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) shares were also up, gaining 18% to $23.50 after the company posted upbeat quarterly earnings.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Perspective Therapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NYSE">CATX</a>) shares dropped 48% to $3.2350. Perspective Therapeutics will pursue dose escalation of [212Pb]VMT-α-NET in its ongoing Phase 1/2a clinical trial based on data presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium.</li>
<li>Shares of Pyxis Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) were down 47% to $2.0389 after the company announced PYX-201 clinical Phase 1 part 1 data.</li>
<li>Kura Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) was down, falling 37% to $10.05. Kura Oncology and Kyowa Kirin disclosed a global strategic collaboration to develop and commercialize Ziftomenib in Acute Leukemias.</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $69.91 while gold traded up 0.6% at $2,668.50.
Silver traded down 0.4% to $30.880 on Thursday, while copper fell 0.7% to $4.1285.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.1%, Germany's DAX gained 0.3% and France's CAC 40 fell 0.1%. Spain's IBEX 35 Index fell 0.2%, while London's FTSE 100 gained 0.5%.
Consumer confidence in the Eurozone fell by 1.2 points to a reading of -13.7 in November.
Asia Pacific Markets
Asian markets closed mostly lower on Thursday, with Japan's Nikkei 225 falling 0.85%, Hong Kong's Hang Seng Index falling 0.53%, China's Shanghai Composite Index gaining 0.07% and India's BSE Sensex falling 0.54%.
Economics
<ul>
<li>U.S. existing home sales gained by 3.5% from the previous month to an annualized rate of 3.96 million in October.</li>
<li>The Philadelphia Fed Manufacturing Index fell to -5.5 in November from 10.3 in the previous month, and compared to market estimates of 8.</li>
<li>U.S. initial jobless claims declined by 6,000 from the previous week to 213,000 in the week ending Nov. 16.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42112636/top-3-tech-stocks-which-could-rescue-your-portfolio-in-q4">Top 3 Tech Stocks Which Could Rescue Your Portfolio In Q4</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

CATX

KURA

NVDA

PYXS

QUBT

SNOW

Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings

Barclays analyst Raimo Lenschow maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Equal-Weight and raises the price target from $142 to $172.

Barclays Maintains Equal-Weight on Snowflake, Raises Price Target to $172

FAA Administrator Says He Plans To Soon Visit Boeing In Seattle To Meet With CEO

Deep-pocketed investors have adopted a bullish approach towards Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TSM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Taiwan Semiconductor. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 53% leaning bullish and 33% bearish. Among these notable options, 3 are puts, totaling $127,002, and 12 are calls, amounting to $1,082,394.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $170.0 and $220.0 for Taiwan Semiconductor, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Taiwan Semiconductor's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Taiwan Semiconductor's substantial trades, within a strike price spectrum from $170.0 to $220.0 over the preceding 30 days.
<h3>Taiwan Semiconductor Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732202321_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$15.75</td>
<td>$15.45</td>
<td>$15.73</td>
<td>$190.00</td>
<td>$314.6K</td>
<td>2.4K</td>
<td align="right">374</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$27.1</td>
<td>$26.4</td>
<td>$26.96</td>
<td>$185.00</td>
<td>$134.8K</td>
<td>1.0K</td>
<td align="right">50</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$26.4</td>
<td>$25.6</td>
<td>$26.07</td>
<td>$185.00</td>
<td>$130.3K</td>
<td>1.0K</td>
<td align="right">100</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$5.55</td>
<td>$5.25</td>
<td>$5.55</td>
<td>$187.50</td>
<td>$111.0K</td>
<td>12.7K</td>
<td align="right">201</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$5.25</td>
<td>$5.2</td>
<td>$5.25</td>
<td>$187.50</td>
<td>$68.2K</td>
<td>12.7K</td>
<td align="right">364</td>
</tr>
</tbody>
</table>

<h3>About Taiwan Semiconductor</h3>
Taiwan Semiconductor Manufacturing Co. is the world's largest dedicated chip foundry, with over 60% market share. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the us in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD, and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs. TSMC employs more than 73,000 people.
In light of the recent options history for Taiwan Semiconductor, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Taiwan Semiconductor Standing Right Now?</h3>
<ul>
<li>With a trading volume of 4,231,883, the price of TSM is up by 0.23%, reaching $188.8.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 56 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Taiwan Semiconductor</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $227.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Taiwan Semiconductor, targeting a price of $215. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Taiwan Semiconductor with a target price of $240. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Taiwan Semiconductor options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Smart Money Is Betting Big In TSM Options

Financial giants have made a conspicuous bullish move on Dell Technologies. Our analysis of options history for Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) revealed 12 unusual trades.
Delving into the details, we found 66% of traders were bullish, while 8% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $107,308, and 9 were calls, valued at $515,995.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $120.0 to $150.0 for Dell Technologies over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Dell Technologies's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Dell Technologies's whale activity within a strike price range from $120.0 to $150.0 in the last 30 days. 
<h3>Dell Technologies Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732202316_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DELL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.55</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$150.00</td>
<td>$225.0K</td>
<td>6.9K</td>
<td>1.0K</td>
</tr>
<tr>
<td>DELL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.95</td>
<td>$10.6</td>
<td>$10.95</td>
<td>$145.00</td>
<td>$60.2K</td>
<td>383</td>
<td>0</td>
</tr>
<tr>
<td>DELL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$1.99</td>
<td>$1.79</td>
<td>$1.79</td>
<td>$135.00</td>
<td>$47.6K</td>
<td>1.9K</td>
<td>502</td>
</tr>
<tr>
<td>DELL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$21.1</td>
<td>$21.05</td>
<td>$21.1</td>
<td>$120.00</td>
<td>$42.2K</td>
<td>3.2K</td>
<td>21</td>
</tr>
<tr>
<td>DELL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$2.79</td>
<td>$2.78</td>
<td>$2.79</td>
<td>$150.00</td>
<td>$41.8K</td>
<td>2.3K</td>
<td>167</td>
</tr>
</tbody>
</table>

<h3>About Dell Technologies</h3>
Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It is focused on premium and commercial personal computers and enterprise on-premises data center hardware. It holds top-three market shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell has a robust ecosystem of component and assembly partners, and also relies heavily on channel partners to fulfill its sales.
<h3>Present Market Standing of Dell Technologies</h3>
<ul>
<li>With a volume of 1,188,427, the price of DELL is up 1.28% at $135.67. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 5 days.</li>
</ul>
<h3>Professional Analyst Ratings for Dell Technologies</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $154.66666666666666.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Dell Technologies, maintaining a target price of $154. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Dell Technologies, which currently sits at a price target of $160. 
&#x2A; An analyst from Evercore ISI Group downgraded its action to Outperform with a price target of $150. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Dell Technologies, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

DELL

Dell Technologies Unusual Options Activity For November 21

Whales with a lot of money to spend have taken a noticeably bullish stance on Oracle.
Looking at options history for Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) we detected 31 trades.
If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish expectations and 35% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $1,437,766 and 28, calls, for a total amount of $1,238,765.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $160.0 to $220.0 for Oracle over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Oracle's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Oracle's substantial trades, within a strike price spectrum from $160.0 to $220.0 over the preceding 30 days.
<h3>Oracle 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732202310_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.57</td>
<td>$1.39</td>
<td>$1.4</td>
<td>$160.00</td>
<td>$1.2M</td>
<td>1.9K</td>
<td>10.0K</td>
</tr>
<tr>
<td>ORCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.4</td>
<td>$1.39</td>
<td>$1.4</td>
<td>$160.00</td>
<td>$166.9K</td>
<td>1.9K</td>
<td>1.1K</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$1.47</td>
<td>$1.2</td>
<td>$1.4</td>
<td>$202.50</td>
<td>$70.0K</td>
<td>3</td>
<td>2.0K</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$1.55</td>
<td>$1.09</td>
<td>$1.4</td>
<td>$202.50</td>
<td>$70.0K</td>
<td>3</td>
<td>1.5K</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$1.44</td>
<td>$1.05</td>
<td>$1.4</td>
<td>$202.50</td>
<td>$70.0K</td>
<td>3</td>
<td>500</td>
</tr>
</tbody>
</table>

<h3>About Oracle</h3>
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Having examined the options trading patterns of Oracle, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Oracle</h3>
<ul>
<li>Trading volume stands at 976,741, with ORCL's price up by 0.53%, positioned at $191.76.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 18 days.</li>
</ul>
<h3>Professional Analyst Ratings for Oracle</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $182.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital downgraded its action to Sector Perform with a price target of $165. 
&#x2A; An analyst from Keybanc persists with their Overweight rating on Oracle, maintaining a target price of $200. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Oracle, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ORCL

Smart Money Is Betting Big In ORCL Options

RBC Capital analyst Sabahat Khan maintains Jacobs Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) with a Outperform and lowers the price target from $167 to $152.

RBC Capital Maintains Outperform on Jacobs Solutions, Lowers Price Target to $152

Barclays analyst Alex Scott maintains Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) with a Underweight and raises the price target from $278 to $302.

Barclays Maintains Underweight on Willis Towers Watson, Raises Price Target to $302

On Thursday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) raised its mid-term sales guidance, increasing its compound annual growth rate (CAGR) target to 6% from 5% for 2023-2028.
The upgrade reflects performance from current growth drivers and anticipated launches, many of which are expected to retain U.S. exclusivity into the 2030s.
The <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-upgrades-mid-term-guidance-and-highlights-deep-pipeline-core-therapeutic-areas-drive-long-term-growth" rel="noreferrer noopener">updated</a> forecast, announced ahead of the company's Meet Novartis Management event in London, underscores its confidence in sustained momentum.
Novartis has outlined its projections for 2024-2029, maintaining a 5% CAGR target with 2024 as the base year.
The company remains on track to achieve a core operating income margin of over 40% by 2027, supported by continued sales growth and productivity enhancements.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41634528/positive-outlook-for-novartis-as-company-capitalizes-on-growing-treatment-opportuni" rel="noreferrer noopener">Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights</a>
The company said the business is gaining strong momentum, with eight marketed brands expected to generate $3 billion to $8 billion at peak sales.
CEO Vas Narasimhan noted increased peak sales estimates for flagship drugs, including Cosentyx, Kisqali, Kesimpta, Pluvicto, and Leqvio, alongside 15 pivotal submission-enabling readouts in the pipeline.
He highlighted the company's long-term strategy, identifying more than 30 promising pipeline assets poised to rejuvenate its portfolio and sustain mid-single-digit growth beyond 2029.
Over the past two years, Novartis has executed more than 30 deals targeting exploratory and preclinical stages. Recent acquisitions, such as Kate Therapeutics and a collaboration with Ratio Therapeutics, bolster its radioligand and gene therapy pipelines, expanding opportunities in neuromuscular and radiotherapeutic advancements.
In October, Novartis reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion. Volume contributed 12 percentage <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41598312/novartis-q3-earnings-beats-expectations-on-strong-sales-from-key-drugs-lifts-2024-outlook" rel="noreferrer noopener">points to growth</a>.
The company said, "All key growth drivers contributed to the momentum. We achieved important indications expansions for&nbsp;Kisqali&nbsp;in early breast cancer and&nbsp;Fabhalta&nbsp;in IgA nephropathy&#8230;"
Novartis has <a target="_blank" href="https://www.novartis.com/stories/addressing-unmet-needs-inherited-neuromuscular-diseases" rel="noreferrer noopener">acquired</a> Kate Therapeutics to enhance and strengthen its portfolio of gene therapies.
Kate Therapeutics is a San Diego-based, preclinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined neuromuscular diseases.&nbsp;
The transaction value is up to $1.1 billion, comprising an upfront payment and potential additional milestone payments.
Kate Therapeutics' primary programs include preclinical candidates for Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and myotonic dystrophy type 1.
Price Action: NVS stock is up 0.24% at $103.34 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42098042/carlyle-sells-quidelortho-shares-analyst-sees-overhang-lifted" target="_blank" rel="noreferrer noopener">Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted</a></li>
</ul>
Photo by Taljat David via Shutterstock

Biotech

Large Cap

Guidance

Health Care

General

Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline

Canaan (CAN) has released an update. Canaan Inc. has entered into a Securities Purchase Agreement to sell newly authorized Series A-1 Convertible P...

Canaan's Strategic Sale of Preferred Shares

Canaan (CAN) has released an update. Canaan Inc. reported a significant boost in its third-quarter 2024 revenue, reaching $73.6 million, marking a ...

Canaan Inc. Sees Revenue Surge Amid Market Challenges

Canaan (CAN) has released an update. Canaan Inc. is expanding its Bitcoin mining footprint in Texas and Pennsylvania through strategic partnerships...

Canaan Expands Bitcoin Mining in North America

Canaan Inc. 2024 Q3 - Results - Earnings Call Presentation

Canaan Inc. (CAN) Q3 2024 Earnings Call Transcript

Canaan Inc. ( ($CAN) ) has released its Q3 earnings. Here is a breakdown of the information Canaan Inc. presented to its investors. Canaan Inc., a ...

Canaan Inc. Reports Strong Q3 2024 Revenue Growth

Bitcoin tops the $97,000 level: A closer look at financial conditions

H.C. Wainwright analyst Kevin Dede reiterated a Buy rating on Canaan (CAN – Research Report) today and set a price target of $3.00. Kevin Dede has ...

Comments

Canaan

Canaan (CAN) 옵션

Canaan (NASDAQ:CAN) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌